|
Patient cohort |
| UC | CD | IBD total |
|
N (%) of patients | 140 (49.3) | 144 (50.7) | 284 (100) |
|
Male/female N (%) | 77 (54.6)/64 (45.4) | 77 (55)/63 (45) | 140 (49.3)/144 (50.7) |
|
Age at enrolment | | | |
|
Disease location N (%) | Available for 110 UC patients: | Available for 125 CD patients (Montreal classification) | |
E1: 11 (10%) | L1: 33 (26.4%) | |
E2: 58 (52.7%) | L2: 42 (33.6%) | |
E3: 41 (37.3%) | L3: 46 (36.8%) | |
| L4: 4 (3.2%) | |
|
EIM frequency N (%) | Available for 139 UC patients: | Available for 142 CD patients: | Available for 281 IBD patients: |
51 (36.7) | 72 (50.7) | 123 (43.8) |
|
Fistula frequency N (%) | Available for 140 UC patients: | Available for 144 CD patients: | Available for 284 IBD patients: |
10 (7.1) | 73 (50.7) | 83 (29.2) |
|
Mean CDAI at enrolment | NA | Available for 127 CD patients: | NA |
|
State of CD (quiescent/acute) N (%) |
NA | Available for 127 CD pat.: |
NA |
95 (74.8)/32 (25.2) |
|
Mean mtwsi at enrolment | Available for 140 UC patients: | NA | NA |
|
State of UC (inactive/active) N (%) | 118 (84.3)/22 (15.7) | NA | NA |
|
Leucocytes at enrolment | Valid for 134 UC patients: | Available for 142 CD patients: | Available for 276 IBD patients: |
|
CRP at enrolment | Valid for 127 CD patients: | Available for 138 CD patients: | Available for 265 IBD patients: |
|
Control cohort |
| | | Control total |
|
N of controls (%) | | | 194 (100) |
Male/female N (%) | | | 77 (39.7)/117 (60.3) |
Age at enrolment | | | |
|